Zacks Investment Research lowered shares of Aratana Therapeutics (NASDAQ:PETX) from a buy rating to a hold rating in a report released on Thursday.
According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “
PETX has been the topic of several other reports. Stifel Nicolaus lowered Aratana Therapeutics from a buy rating to a hold rating and reduced their price target for the stock from $8.00 to $5.00 in a research report on Friday, January 11th. William Blair lowered Aratana Therapeutics from an outperform rating to a market perform rating and set a $4.14 price target on the stock. in a research report on Thursday, January 24th. BidaskClub lowered Aratana Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, January 11th. Finally, TheStreet upgraded Aratana Therapeutics from a d rating to a c- rating in a research report on Wednesday, November 21st. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Aratana Therapeutics currently has a consensus rating of Hold and a consensus target price of $6.41.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Tuesday, March 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.06). The firm had revenue of $4.91 million for the quarter, compared to analysts’ expectations of $6.53 million. Aratana Therapeutics had a negative net margin of 41.57% and a negative return on equity of 14.84%. As a group, equities analysts expect that Aratana Therapeutics will post -0.28 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James & Associates bought a new stake in shares of Aratana Therapeutics in the 4th quarter worth approximately $65,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Aratana Therapeutics in the 4th quarter worth approximately $88,000. Metropolitan Life Insurance Co. NY grew its position in shares of Aratana Therapeutics by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 17,040 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 13,308 shares during the last quarter. Creative Planning bought a new stake in shares of Aratana Therapeutics in the 4th quarter worth approximately $127,000. Finally, Hollencrest Capital Management bought a new stake in shares of Aratana Therapeutics in the 4th quarter worth approximately $153,000. Institutional investors and hedge funds own 68.64% of the company’s stock.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.
Featured Story: Municipal Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.